Radiotherapy cannot prolong overall survival of young prostate cancer patients with bone metastases

Table 4 Multivariate analysis for survival

Factors	β	S.e.	RR	P value
Radiotherapy on metastasis sites	0.209	0.289	1.233	0.469
Chemotherapy	−0.198	0.316	0.820	0.530
Gleason scores when diagnosed as Pca^a				0.876
2–4	−0.507	1.037	0.602	0.625
5–7	−0.054	0.277	0.948	0.846
PSA when bone metastases occurred^b				0.569
<4 ng ml⁻¹	0.492	0.475	1.635	0.301
4–20 ng ml⁻¹	0.214	0.489	1.239	0.661
ALP when bone metastases occurred	0.461	0.251	1.586	0.041
The number of bone metastases	0.889	0.410	2.433	0.030
Regional lymph node metastases	0.580	0.321	1.786	0.071
Metastases when bone metastases occurred^c				0.957
Without	−0.108	0.443	0.897	0.807
Neighbouring organs	−0.050	0.511	0.951	0.922

ALP alkaline phosphatase; β coefficient of regression; PCa prostate cancer; RR relative risk; s.e. standard error
^a Gleason 8–10 used as control group
^b PSA > 20 ng ml-1 used as control group
^c Distant organs used as control group

ISSN: 1479-5876